Panther Biotechnology is Biotechnology in United States that focus on molecule therapeutics business. Founded in 2011. They cover business area such as developer, small molecule therapeutic, neoplastic, autoimmune and antiviral disorder, transferrin glycoprotein, Doxorubicin, target delivery, tumor, reduce side effect, leukemia, lymphoma and myeloma patient, treatment, a high likelihood.
2011
( 13 years old in 2024 )
Molecule Therapeutics
-
888 Prospect Street
Suite 200
La Jolla, CA 92037
United States
Private
developersmall molecule therapeuticneoplastic, autoimmune and antiviral disordertransferrin glycoproteinDoxorubicintarget deliverytumorreduce side effectleukemialymphoma and myeloma patienttreatmenta high likelihood
* We use standard office opening hours in near Panther Biotechnology's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Panther Biotechnology is Biotechnology business from United States that founded in 2011 (13 years old in 2024), Panther Biotechnology business is focusing on Molecule Therapeutics.
Panther Biotechnology headquarter office and corporate office address is located in 888 Prospect Street Suite 200 La Jolla, CA 92037 United States.
Panther Biotechnology was founded in United States.
In 2024, Panther Biotechnology is currently focus on molecule therapeutics sector.
Above is snippet of Google Trends for "molecule therapeutics" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Panther Biotechnology, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
